SG11201908376UA - Methods and compositions for inducing immune responses against clostridium difficile - Google Patents
Methods and compositions for inducing immune responses against clostridium difficileInfo
- Publication number
- SG11201908376UA SG11201908376UA SG11201908376UA SG11201908376UA SG 11201908376U A SG11201908376U A SG 11201908376UA SG 11201908376U A SG11201908376U A SG 11201908376UA SG 11201908376U A SG11201908376U A SG 11201908376UA
- Authority
- SG
- Singapore
- Prior art keywords
- novavax
- gaithersburg
- maryland
- road
- international
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 241000193163 Clostridioides difficile Species 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 239000003053 toxin Substances 0.000 abstract 4
- 231100000765 toxin Toxicity 0.000 abstract 4
- 108700012359 toxins Proteins 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471636P | 2017-03-15 | 2017-03-15 | |
| US201762474434P | 2017-03-21 | 2017-03-21 | |
| PCT/US2018/022597 WO2018170238A2 (en) | 2017-03-15 | 2018-03-15 | Methods and compositions for inducing immune responses against clostridium difficile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908376UA true SG11201908376UA (en) | 2019-10-30 |
Family
ID=63523217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908376U SG11201908376UA (en) | 2017-03-15 | 2018-03-15 | Methods and compositions for inducing immune responses against clostridium difficile |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123419B2 (he) |
| EP (1) | EP3595709A4 (he) |
| JP (2) | JP7149285B2 (he) |
| KR (1) | KR102640722B1 (he) |
| CN (1) | CN110691609B (he) |
| AU (1) | AU2018236352B2 (he) |
| BR (1) | BR112019019117A2 (he) |
| CA (1) | CA3056090A1 (he) |
| IL (1) | IL269258B2 (he) |
| MX (1) | MX2019010948A (he) |
| SG (1) | SG11201908376UA (he) |
| WO (1) | WO2018170238A2 (he) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4365196A2 (en) | 2011-04-22 | 2024-05-08 | Wyeth LLC | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| KR102640722B1 (ko) | 2017-03-15 | 2024-02-26 | 노바백스, 인코포레이티드 | 클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물 |
| US20230218735A1 (en) * | 2020-06-19 | 2023-07-13 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| JP2002509943A (ja) * | 1997-09-04 | 2002-04-02 | イーストマン ケミカル カンパニー | 固相重合速度を高める熱可塑性ポリウレタン添加剤 |
| WO2010017383A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| US20130039973A1 (en) * | 2011-08-03 | 2013-02-14 | Henry J. Smith | Viral Immunogenic Compositions |
| WO2013049342A1 (en) | 2011-09-30 | 2013-04-04 | Novavax, Inc. | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| LT2928489T (lt) | 2012-12-05 | 2019-04-10 | Glaxosmithkline Biologicals S.A. | Imunogeninė kompozicija |
| GB201223342D0 (en) | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2988778A4 (en) | 2013-04-22 | 2016-12-14 | Board Of Regents Of The Univ Of Oklahoma | CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE |
| EP3524262A1 (en) * | 2013-11-01 | 2019-08-14 | Pfizer Inc | Vectors for expression of prostate-associated antigens |
| ES2749701T3 (es) * | 2014-06-25 | 2020-03-23 | Glaxosmithkline Biologicals Sa | Composición inmunógena de Clostridium difficile |
| CN106220737B (zh) * | 2016-07-21 | 2020-11-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 融合蛋白及其在治疗艰难梭菌相关疾病中的应用 |
| KR102640722B1 (ko) | 2017-03-15 | 2024-02-26 | 노바백스, 인코포레이티드 | 클로스트리듐 디피실에 대한 면역 반응을 유도하기 위한 방법 및 조성물 |
-
2018
- 2018-03-15 KR KR1020197030108A patent/KR102640722B1/ko active IP Right Grant
- 2018-03-15 MX MX2019010948A patent/MX2019010948A/es unknown
- 2018-03-15 EP EP18767173.0A patent/EP3595709A4/en active Pending
- 2018-03-15 AU AU2018236352A patent/AU2018236352B2/en active Active
- 2018-03-15 IL IL269258A patent/IL269258B2/he unknown
- 2018-03-15 US US16/494,517 patent/US11123419B2/en active Active
- 2018-03-15 CN CN201880025192.8A patent/CN110691609B/zh active Active
- 2018-03-15 WO PCT/US2018/022597 patent/WO2018170238A2/en unknown
- 2018-03-15 JP JP2019550687A patent/JP7149285B2/ja active Active
- 2018-03-15 BR BR112019019117A patent/BR112019019117A2/pt unknown
- 2018-03-15 CA CA3056090A patent/CA3056090A1/en active Pending
- 2018-03-15 SG SG11201908376U patent/SG11201908376UA/en unknown
-
2021
- 2021-08-10 US US17/398,610 patent/US11938179B2/en active Active
-
2022
- 2022-09-26 JP JP2022153071A patent/JP7397145B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019010948A (es) | 2020-01-09 |
| JP7397145B2 (ja) | 2023-12-12 |
| CN110691609A (zh) | 2020-01-14 |
| CN110691609B (zh) | 2024-04-19 |
| WO2018170238A3 (en) | 2018-10-18 |
| US11123419B2 (en) | 2021-09-21 |
| KR20190125470A (ko) | 2019-11-06 |
| BR112019019117A2 (pt) | 2020-05-05 |
| JP2020509770A (ja) | 2020-04-02 |
| JP2022179543A (ja) | 2022-12-02 |
| KR102640722B1 (ko) | 2024-02-26 |
| AU2018236352B2 (en) | 2024-04-04 |
| US11938179B2 (en) | 2024-03-26 |
| AU2018236352A1 (en) | 2019-10-03 |
| JP7149285B2 (ja) | 2022-10-06 |
| RU2019132111A3 (he) | 2021-06-29 |
| IL269258B2 (he) | 2023-09-01 |
| CA3056090A1 (en) | 2018-09-20 |
| IL269258B1 (he) | 2023-05-01 |
| EP3595709A4 (en) | 2020-12-23 |
| RU2019132111A (ru) | 2021-04-15 |
| WO2018170238A2 (en) | 2018-09-20 |
| US20200085934A1 (en) | 2020-03-19 |
| US20220211834A1 (en) | 2022-07-07 |
| EP3595709A2 (en) | 2020-01-22 |
| IL269258A (he) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908376UA (en) | Methods and compositions for inducing immune responses against clostridium difficile | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201900028VA (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201811227QA (en) | Method for facilitating maturation of the mammalian immune system | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201900038QA (en) | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201810549TA (en) | Hiv vaccine formulation | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201902531QA (en) | Liquid pharmaceutical composition |